Key result
A 78-year-old woman with a history of malignancy and autoimmune disease developed spontaneous hemorrhagic pericardial and pleural effusions shortly after initiating apixaban for a pulmonary embolism.
Why the study?
The efficacy and side effect profile of DOACs have not been widely studied in specific cohorts, such as cancer patients and those on immunomodulators or hormone analogs.
Case Report (n=1)
No
Apixaban use in patients with complex comorbidities, including malignancy and autoimmune disease, may be associated with severe bleeding complications such as spontaneous hemorrhagic pericardial and pleural effusions.
Answers are grounded in this paper and cite their sources.
May warrant caution with apixaban in malignancy or autoimmune disease; single case leaves causality and generalizability open.
Direct oral anticoagulants (DOACs) are used for many conditions where anticoagulation is needed such as non-valvular atrial fibrillation, deep vein thrombosis (DVT) and pulmonary embolism (PE). These novel agents have become popular since they do not require monitoring of therapeutic levels and there is a lower risk of certain bleeding complications when compared to warfarin. However, the efficacy and side effect profile of these agents have not been widely studied in certain patient cohorts, namely cancer patients and patients on immunomodulators or hormone analogs. We present a case of a patient with a history of malignancy and autoimmune disease who developed pericardial and pleural effusions shortly after initiating apixaban for treatment of a PE. In addition, we aim to increase awareness of the role that the newly available reversal agents for anticoagulants would offer in the acute management of hemorrhagic pericardial and pleural effusions caused by DOACs in patients with and without malignancy.
No takes yet. Share an insight, caveat, or question.
Cinelli et al. (2019) conducted a case report in Pulmonary embolism and atrial fibrillation (n=1). Apixaban was evaluated. A 78-year-old woman with a history of malignancy and autoimmune disease developed spontaneous hemorrhagic pericardial and pleural effusions shortly after initiating apixaban for a pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: